Laurel Wealth Advisors (North Carolina)’s LogicBio Therapeutics, Inc. Common Stock LOGC Stock Holding History

Laurel Wealth Advisors (North Carolina)’s Portfolio LOGC Stock Details LOGC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-1,700	Closed	-$1K	–	638
2022 Q2	$1K	Hold	1,700	–	–	﹤0.01%	625
2022 Q1	$1K	Hold	1,700	–	–	﹤0.01%	661
2021 Q4	$4K	Hold	1,700	–	–	﹤0.01%	522
2021 Q3	$8K	Buy	1,700 +800	+89%	+$3.52K	﹤0.01%	430
2021 Q2	$4K	Buy	+900	New	+$4.58K	﹤0.01%	592

Other funds holding LOGC

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Prudential Financial Newark, New Jersey $81.2B AUM 27.81% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

BCM

Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Laurel Wealth Advisors (North Carolina)'s LOGC Position: Q3 2022 in Review

Laurel Wealth Advisors (North Carolina) sold out of LogicBio Therapeutics, Inc. Common Stock (LOGC) in Q3 2022, closing a stake of 1,700 shares — an estimated $1K sold.

Laurel Wealth Advisors (North Carolina) first reported a position in LOGC in Q2 2021 and held it in 5 quarters. The position peaked at $8K in Q3 2021. 39 funds tracked by Wall St. Rank hold LOGC as of Q3 2022.

Laurel Wealth Advisors (North Carolina) reported no remaining LogicBio Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Laurel Wealth Advisors (North Carolina) sold 1,700 LogicBio Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1K.
Laurel Wealth Advisors (North Carolina) first reported a position in LogicBio Therapeutics, Inc. Common Stock in Q2 2021 and held it in 5 quarters.
Laurel Wealth Advisors (North Carolina)'s LogicBio Therapeutics, Inc. Common Stock position peaked at $8K in Q3 2021.
39 funds tracked by Wall St. Rank held LogicBio Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Laurel Wealth Advisors (North Carolina)'s 13F filing for Q3 2022, filed 15 Nov 2022.